Introduce Amivantamab in Central Vein, Perc, New Tech 7

This code describes the administration of amivantamab, a targeted monoclonal antibody therapy, directly into a central vein. This procedure is performed using a percutaneous approach, meaning through the skin, typically via a central venous catheter. It signifies the use of a novel therapeutic agent for specific oncological conditions.

This code is used when amivantamab is delivered intravenously into a central line for the treatment of advanced non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations. It applies to inpatient encounters where this specific new technology drug is administered via a central venous access device.

• Ensure documentation clearly specifies amivantamab as the substance introduced and a central vein as the access site.
• Verify the approach is percutaneous; if an open approach is used, a different code would be appropriate.
• Confirm the patient's diagnosis aligns with the indications for amivantamab, such as EGFR exon 20 insertion-mutated NSCLC.